b
r
c
virus
quickli
spread
mammalian
host
carri
risk
humantohuman
transmiss
shown
outbreak
acut
respiratori
distress
syndrom
ard
lung
failur
fulmin
pneumonia
major
lung
diseas
patient
transplant
mesenchym
stem
cell
msc
promis
choic
treat
virusinduc
pneumonia
use
treat
ard
transplant
msc
patient
ard
conduct
singl
center
openlabel
clinic
trial
base
principl
voluntari
inform
consent
patient
ard
includ
control
group
patient
ard
act
experiment
group
allogen
menstrualbloodderiv
msc
notabl
msc
transplant
significantli
lower
mortal
experiment
group
compar
control
group
die
experiment
group
die
control
group
furthermor
msc
transplant
result
harm
effect
bodi
four
patient
part
fiveyear
followup
period
collect
result
suggest
msc
significantli
improv
surviv
rate
ard
provid
theoret
basi
treatment
ard
preclin
research
clinic
studi
corona
viru
diseas
share
similar
complic
eg
ard
lung
failur
correspond
multiorgan
dysfunct
mscbase
therapi
could
possibl
altern
treat
influenza
virus
iav
divid
multipl
subtyp
accord
diversifi
viral
surfac
antigen
two
major
pathotyp
includ
high
low
pathogen
chicken
among
iav
avian
virus
high
pathogen
belong
subtyp
recent
novel
avianorigin
influenza
viru
emerg
spring
unfortun
led
sever
fatal
respiratori
diseas
human
novel
viru
similar
phylogenet
genom
viru
isol
chicken
found
live
poultri
market
viru
one
mani
reassort
virus
primarili
deriv
subtyp
iav
although
pathogen
low
chicken
human
much
suscept
transmiss
particularli
live
poultri
market
intim
contact
chicken
virus
abl
spread
mammalian
host
ferret
without
lose
virul
genet
mutat
viru
confer
risk
humantohuman
transmiss
demonstr
famili
cluster
infect
viru
six
season
epidem
sinc
first
case
emerg
epidem
resurg
viru
mainland
china
sinc
suggest
becom
virul
therefor
defend
http
author
publish
elsevi
ltd
behalf
chines
academi
engin
higher
educ
press
limit
compani
open
access
articl
cc
byncnd
licens
http
acut
respiratori
distress
syndrom
ard
instrument
cure
patient
ard
lung
failur
fulmin
pneumonia
major
lung
diseas
patient
viru
caus
extrapulmonari
diseas
includ
rhabdomyolysi
encephalopathi
cytokin
storm
vivo
current
vaccin
avail
prevent
infect
extens
therapeut
intervent
eg
extracorpor
membran
oxygen
ecmo
continu
renal
replac
therapi
crrt
appli
infecti
patient
sever
howev
deal
antivir
resist
secondaryinfectioninduc
multipl
organ
dysfunct
patient
still
seriou
concern
exig
demand
explor
effect
strategi
infect
human
sever
acut
respiratori
syndrom
coronaviru
garner
global
attent
caus
coronaviru
diseas
wuhan
china
number
infect
patient
risen
rapidli
due
lack
suffici
awar
proxim
peopl
eas
mobil
humantohuman
transmiss
abil
viru
presnet
effect
way
cure
share
similar
complic
eg
ard
lung
failur
correspond
multiorgan
dysfunct
lung
inflammatori
lesion
structur
damag
henc
breakthrough
treatment
strategi
infect
human
would
critic
treat
especi
ardsinduc
sever
pneumonia
current
caus
panic
around
world
effort
control
lung
injuri
via
pharmacolog
agent
unsuccess
mesenchym
stem
cell
msc
base
therapi
investig
base
msc
limitless
selfrenew
multipot
furthermor
mscbase
therapi
demonstr
promis
effect
experiment
treatment
ard
via
inhibit
alveolar
collaps
collagen
accumul
cell
apoptosi
lung
tissu
recent
wilson
et
al
found
administr
allogen
msc
nine
patient
ard
result
prespecifi
advers
event
includ
hypoxaemia
cardiac
arrhythmia
ventricular
tachycardia
menstrualbloodderiv
msc
current
attract
interest
due
sourc
potenti
high
prolifer
rate
painless
procedur
free
ethic
issu
studi
first
trial
test
menstrualbloodderiv
msc
patient
ard
report
effect
transplant
differ
stage
ard
assess
longterm
safeti
improv
pulmonari
function
infect
msc
transplant
studi
contribut
field
pilot
clinic
studi
show
function
msc
ard
also
suggest
msc
promis
tool
treat
acut
pneumonia
futur
clinic
use
studi
msc
transplant
patient
ard
conduct
singl
center
openlabel
clinic
trial
research
ethic
committe
first
affili
hospit
colleg
medicin
zhejiang
univers
approv
implement
clinic
studi
patient
confirm
infect
enrol
admit
hospit
march
februari
patient
confirm
base
clinic
syndrom
similar
acut
influenza
includ
fever
cough
short
breath
patient
studi
confirm
via
laboratori
test
express
specif
gene
serum
antibodi
patient
ard
defin
pao
fio
less
mmhg
mmhg
pa
bilater
infiltr
coher
pulmonari
edema
use
frontal
chest
radiograph
requir
applic
mechan
ventil
endotrach
tracheal
tube
seventeen
voluntari
patient
ard
provid
inform
consent
made
experiment
group
undergo
msc
transplant
patient
ard
act
control
group
without
msc
transplant
unlik
studi
infus
msc
acut
phase
late
stage
ard
allogen
menstrualbloodderiv
msc
obtain
healthi
femal
donor
age
sign
inform
consent
donat
state
previous
treatment
author
research
ethic
committe
first
affili
hospit
colleg
medicin
zhejiang
univers
mononuclear
cell
menstrual
blood
examin
nucleat
cell
cell
differenti
cell
viabil
steril
prior
seed
cultur
confluenc
msc
cell
passag
prior
use
msc
resuspend
plasmalytea
baxter
toronto
canada
local
laboratori
special
cell
therapi
center
total
usag
msc
ml
patient
experiment
group
laboratori
index
blood
sampl
liver
function
inflamm
index
renal
function
myocardi
enzym
carri
laboratori
depart
first
affili
hospit
colleg
medicin
zhejiang
univers
factor
could
correl
clinic
featur
therapeut
outcom
patient
ard
analyz
baselin
characterist
includ
age
underli
condit
symptom
data
laboratori
examin
imag
scan
combin
treatment
basic
therapi
antivir
therapi
antibiot
therapi
vasoact
drug
glucocorticoid
therapi
mechan
ventil
ecmo
artifici
liver
support
system
alss
crrt
particip
patient
oral
administr
drug
oseltamivir
peramivir
accord
standard
therapi
antibiot
given
base
posit
result
blood
test
throatswab
specimen
sputum
test
bacteri
infect
oxygen
inhal
noninvas
ventil
invas
ventil
conduct
maintain
minimum
sao
addit
ecmo
perform
via
femor
intern
jugular
vein
cannul
pao
fio
combin
monotherapi
norepinephrin
dopamin
epinephrin
also
appli
patient
unstabl
haemodynam
addit
patient
also
receiv
glucocorticoid
therapi
includ
methylprednisolon
dexamethason
control
inflammatori
respons
critic
patient
unstabl
haemodynam
multipl
organ
dysfunct
includ
acut
kidney
injuri
fluid
overload
pulmonari
edema
sever
electrolyt
imbal
start
crrt
patient
develop
acut
liver
failur
accept
alss
sever
time
msc
laboratori
alert
inform
consent
obtain
doctor
observ
hemodynam
respiratori
paramet
onehour
period
bedsid
observ
ensur
patient
statu
stabl
prior
msc
transplant
infus
initi
use
standard
blood
filter
tube
set
investig
stay
bedsid
uninterrupt
observ
case
sign
advers
reaction
three
patient
treat
three
infus
msc
earli
stage
infect
six
patient
treat
three
infus
msc
late
stage
infect
eight
patient
accept
four
infus
msc
late
stage
infect
inject
dose
msc
determin
million
per
kilogram
bodi
weight
time
mscinfusionrel
acut
toxic
serious
advers
event
found
patient
multipl
intraven
infus
msc
toler
patient
moder
sever
ard
laboratori
index
blood
sampl
liver
function
inflamm
index
renal
function
myocardi
enzym
conduct
msc
transplant
immedi
msc
transplant
paramet
also
follow
week
month
month
month
month
patient
evalu
comput
tomographi
chest
cct
short
term
month
intermedi
term
month
long
term
month
msc
transplant
patient
evalu
lung
ventilatori
function
month
followup
moreov
item
shortform
health
survey
chines
version
medic
outcom
studi
complet
month
msc
transplant
evalu
healthrel
qualiti
life
hrqol
patient
unabl
perform
facetofac
interview
call
made
obtain
surviv
inform
sampl
size
studi
small
univari
analysi
use
kolmogorovsmirnov
test
appli
check
normal
correspond
quantit
data
baselin
data
exhibit
mean
standard
deviat
sd
median
valu
assess
differ
data
student
test
administr
mannwhitney
utest
analysi
util
nonnumer
data
fisher
exact
test
analyz
examin
categor
variabl
one
sampl
test
appli
evalu
score
month
followup
statist
analysi
conduct
pasw
statist
softwar
version
spss
chicago
il
usa
p
consid
statist
signific
karyotypinggband
msc
normal
viabil
rang
addit
surfac
mark
threelin
differenti
msc
also
conduct
confirm
previou
studi
patient
experiment
group
control
group
receiv
antivir
agent
accord
standard
therapi
fig
show
consort
diagram
clinic
trial
shown
tabl
patient
experiment
group
control
group
averag
age
patient
experiment
group
control
group
respect
health
condit
list
tabl
shock
fig
consort
diagram
clinic
trial
infect
patient
fortyfour
patient
induc
ard
includ
control
group
patient
ard
act
experiment
group
allogen
menstrualbloodderiv
msc
msc
transplant
significantli
lower
mortal
compar
control
group
followup
laboratori
test
taken
four
ard
patient
experiment
group
five
year
complic
hat
frequent
experiment
group
studi
p
indic
patient
ard
experiment
group
underw
sever
circulatori
disturb
eventu
patient
control
group
die
three
patient
die
experiment
group
experiment
group
significantli
higher
surviv
rate
control
group
experiment
group
versu
control
group
p
fourteen
patient
receiv
antibiot
therapi
experiment
group
patient
receiv
antibiot
therapi
control
group
twelv
patient
experiment
group
patient
control
group
receiv
vasoact
drug
due
unstabl
circul
nine
patient
experiment
group
patient
control
group
receiv
glucocorticoid
therapi
fourteen
patient
experiment
group
patient
control
group
receiv
mechan
ventil
eight
patient
experiment
group
patient
control
group
treat
ecmo
thirtyon
patient
includ
experiment
group
control
group
treat
alss
twentyeight
patient
includ
experiment
group
control
group
receiv
crrt
except
alss
crrt
frequenc
standard
strategi
use
two
group
differ
studi
shown
tabl
total
ard
patient
experiment
group
control
group
suffer
fever
patient
experiment
group
patient
control
group
major
patient
experiment
group
suffer
cough
phlegm
short
breath
fatigu
patient
experiment
group
suffer
yellow
sputum
hemoptysi
muscular
sore
comparison
major
patient
control
group
suffer
cough
phlegm
short
breath
patient
control
group
suffer
yellow
sputum
hemoptysi
fatigu
muscular
sore
proport
patient
correspond
symptom
experiment
group
control
group
without
statist
signific
shown
tabl
baselin
laboratori
featur
show
statist
signific
differ
blood
routin
index
inflamm
index
liver
function
renal
function
coagul
two
group
procalcitonin
level
creactiv
protein
level
higher
control
group
experiment
group
p
valu
former
indic
patient
two
group
compar
studi
howev
blood
routin
index
differ
significantli
experiment
group
control
group
patient
discharg
tabl
procalcitonin
level
significantli
higher
control
group
experiment
group
also
serum
creatinin
level
significantli
higher
control
group
experiment
group
versu
p
show
control
group
higher
proport
critic
ill
patient
sever
renal
injuri
level
creatin
kinas
prothrombin
time
pt
ddimer
significantli
higher
control
group
compar
experiment
group
major
laboratori
featur
group
similar
signific
differ
may
associ
higher
death
rate
patient
control
group
number
bracket
repres
proport
patient
correspond
characterist
copd
chronic
obstruct
pulmonari
diseas
ckd
chronic
kidney
diseas
shown
tabl
hemoglobin
level
significantli
upregul
msc
transplant
level
pt
downregul
indic
msc
transplant
exert
harm
effect
patient
bodi
fiveyear
followup
period
four
patient
msc
transplant
includ
index
assess
lung
function
follow
five
year
tabl
ventil
diffus
dysfunct
persist
acut
stage
evalu
lung
function
year
followup
signific
differ
function
forc
expiratori
volum
one
second
forc
vital
capac
fvc
forc
expiratori
flow
vital
capac
among
four
patient
follow
five
year
msc
treatment
patient
show
groundglass
opac
amalgam
onset
diseas
chest
radiographi
describ
follow
four
patient
msc
treatment
five
year
found
radiolog
chang
includ
linear
fibrosi
air
bronchogram
bronchiectasia
isol
area
pleural
thicken
ground
glass
opac
hydrothorax
msc
transplant
chang
subsequ
elimin
pneumatocel
new
node
observ
use
cct
week
fig
fig
appendix
msc
transplant
week
one
year
patient
show
improv
cct
scale
chosen
assess
life
qualiti
four
patient
msc
transplant
follow
two
year
found
score
element
significantli
differ
followup
tabl
appendix
therefor
indic
msc
transplant
influenc
longterm
life
qualiti
patient
patient
suffer
infect
alway
produc
similar
symptom
includ
fever
cough
short
breath
sputum
patient
rapidli
develop
sever
pneumonia
moderatetosever
ard
septic
shock
due
reason
gao
et
al
demonstr
develop
refractori
hypoxemia
one
major
caus
death
system
inflammatori
respons
syndrom
sir
may
serv
main
lethal
factor
pathogenesi
accord
observ
clinic
symptom
amelior
month
data
shown
post
standard
therapi
combin
therapi
msc
transplant
death
rate
control
group
death
rate
experiment
group
case
pulmonari
embol
occur
patient
find
indic
msc
therapi
safe
effect
treatment
patient
sever
lung
diseas
induc
also
evid
mscassoci
longterm
advers
event
studi
zheng
et
al
recent
conclud
patient
moder
sever
ard
develop
infus
toxic
mscrelat
seriou
advers
event
although
sourc
dose
msc
studi
differ
use
zheng
et
al
find
consist
regard
toler
safeti
encourag
patient
ard
signific
improv
lung
function
followup
previous
report
ard
patient
chang
patient
condit
month
discharg
significantli
better
month
research
longterm
prognosi
ard
survivor
show
mildli
restrict
type
lung
function
moder
decreas
carbon
oxid
co
diffus
capac
month
msc
transplant
addit
pulmonari
function
patient
discov
almost
normal
except
reduc
spread
role
respiratori
abil
oneyear
followup
fibrosi
pulmonari
tabl
lung
function
test
four
ard
patient
experiment
group
followup
five
year
week
parenchym
dysfunct
common
clinic
phenomena
sever
ard
infect
time
imag
reveal
signific
improv
lung
function
fibrosi
improv
particularli
evid
first
six
month
discharg
hospit
addit
month
followup
groundglass
opac
significantli
improv
patient
howev
signific
differ
observ
interstiti
fibrosi
groundglass
opac
oneyear
followup
characterist
consist
survivor
suffer
infect
current
clinic
trial
investig
found
patient
return
home
lack
basic
activ
usual
isol
rel
neighbor
peopl
afraid
infect
hundr
peopl
die
survivor
obvious
lower
hrqol
normal
popul
may
result
defici
social
function
mental
health
moreov
metaanalysi
indic
ard
survivor
improv
function
hrqol
initi
six
month
discharg
hospit
report
indic
qualiti
life
ard
survivor
infect
iav
rather
wors
peopl
histori
iav
infect
thu
recommend
emphasi
care
patient
recoveri
focu
creat
social
interact
present
infect
sarslik
viru
widespread
wuhan
even
rest
china
surprisingli
abil
humantohuman
transmiss
sinc
middl
decemb
march
case
report
global
china
number
death
reach
thu
far
thousand
infect
patient
suffer
serv
ard
without
effect
treatment
recent
xu
et
al
confirm
patient
caus
sever
pneumonia
accord
patholog
characterist
die
sever
infect
ard
biopsi
sampl
obtain
autopsi
descript
patholog
featur
ard
appear
strikingli
similar
ard
infect
patient
patient
share
similar
symptom
includ
fever
cough
short
breath
sputum
dyspnea
accompani
ard
later
pulmonari
fibrosi
thu
patient
sever
symptom
ard
might
benefit
novel
method
includ
mscbase
therapi
knowledg
first
prospect
systemat
report
ard
assess
health
condit
convalesc
period
howev
limit
clinic
trial
first
foremost
studi
limit
number
patient
singlecent
studi
patient
use
msc
guarante
everi
step
perfect
phase
one
time
clinic
trial
second
state
routin
clinic
trial
owe
outbreak
lack
better
option
treat
patient
sever
ard
therefor
patient
want
visit
patient
refus
attend
complet
followup
thu
still
concern
longterm
safeti
msc
transplant
treat
ard
despit
lack
side
effect
observ
clinic
trial
moreov
although
patient
may
potenti
lung
infect
receiv
drug
without
examin
possibl
obtain
ideal
comparison
lung
function
indic
experiment
group
control
group
final
limit
small
sampl
size
difficult
obtain
huge
amount
clinic
data
also
difficult
conduct
clinic
studi
critic
ill
patient
suffer
ard
common
side
effect
still
requir
attent
msc
applic
part
clinic
medicin
although
msc
transplant
show
numer
promis
result
longterm
safeti
remain
matter
debat
especi
sinc
diffcult
manag
longterm
followup
patient
concern
msc
potenti
inhibit
tumor
immun
respons
also
gener
new
blood
vessel
may
promot
tumor
growth
metastasi
although
msc
shown
great
promis
treatment
immunolog
diseas
especi
graftversushost
diseas
gvhd
variabl
msc
qualiti
differ
donor
tissu
wide
treatment
protocol
dose
inject
mode
inconsist
experiment
procedur
factor
may
limit
therapeut
effect
msc
clinic
applic
overcom
obstacl
care
evalu
appropri
cell
sourc
scientif
data
comprehens
systemat
understand
msc
immunosuppress
need
clinic
result
believ
msc
abil
reduc
inflammatori
effect
defend
cytokin
storm
although
group
report
prior
clinic
studi
patient
understand
detail
mechan
still
necessari
order
understand
potenti
msc
treat
ard
shown
previou
work
msc
abil
improv
lung
function
antiinflammatori
effect
acut
injuri
lung
mous
model
thu
underli
mechan
like
msc
reduc
secret
inflammatori
factor
although
clinic
studi
msc
still
infanc
optimist
msc
includ
differ
sourc
promis
tool
futur
clinic
applic
summari
longterm
lung
dysfunct
survivor
remain
problem
even
two
year
hospit
discharg
notabl
msc
transplant
significantli
lower
mortal
furthermor
seriou
advers
effect
found
msc
transplant
fiveyear
followup
period
studi
current
conduct
clinic
trial
patient
moder
sever
ard
primari
focu
longterm
safeti
secondari
focu
regul
respiratori
system
improv
qualiti
life
